Supplementary Materialsfig 1. in individual leukocyte antigen-A*0201 and tumor-antigen-positive sufferers with progressing metastatic solid tumors who acquired failed regular therapy. Defense monitoring was carried out by tetramer and enzymatic-linked immune spot analysis. The treatment was well tolerated, with no significant…